StockData
Zimmer Biomet Holdings, Inc. logo

Zimmer Biomet Holdings, Inc. (ZBH) KPIs and segments

ZBHNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3018% below fair value
$103.32+1.23 (+1.20%)

Close on Nov 18, 2026Market cap $19.71BP/E 25.1Yield 0.93%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Zimmer Biomet · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Zimmer Biomet: 42 chỉ số vận hành, trong đó có Product Sales Volume & Mix Growth Effect, Global Average Selling Price Effect và Consolidated Constant-Currency Net Sales Growth, lấy từ 227 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Knees($M)
829829911792826793839745801788798
S.E.T($M)
586562588542551471489454470453453
Hips($M)
563524555506536496520482507491505
Technology & Data, Bone Cement and Surgical($M)
199172190161165150175143165157
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
Americas($M)
1,3591,3251,4131,2541,2871,2071,2731,1361,1991,1871,213
United States($M)
1,2401,2091,3131,1641,1741,1141,1811,0521,1061,0991,128
International($M)
937877837904796842772836790812
EMEA($M)
479490501417458442438376432445426
Asia Pacific($M)
340272329331332261313312310258301
Americas($M)
546529723647536509695605637639665
EMEA($M)
151152166122154151164124152155163
Asia Pacific($M)
1049311711712088.812212312294.4119
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
Americas($M)
1,0501,0271,0989839949391,010901951950
EMEA($M)
296304314257292276287244282290
Asia Pacific($M)
215184210215215177210214211183
Product Sales Volume & Mix Growth Effect(%)1
4.4%5.5%7.2%8.4%5.2%2.2%3.4%4.8%4.2%
Paragon 28 Acquisition Volume Contribution — Consolidated (Legacy through FY2026Q2)(%)3
0.7%3.9%3.8%3.6%2.6%
Paragon 28 Acquisition Contribution — S.E.T. Category (Legacy through FY2026Q2)(%)
2.8%15.8%15.8%14.6%11.1%
Paragon 28 Acquisition Contribution — United States (Legacy through FY2026Q2)(%)
1.0%5.4%5.4%5.0%3.8%
Paragon 28 Acquisition Contribution — International (Legacy through FY2026Q2)(%)
0.4%1.7%1.6%1.7%1.2%
Global Average Selling Price Effect(%)1
-0.7%-0.8%-0.4%0.2%0.2%0.1%0.7%0.8%0.2%
Consolidated Pricing Impact (Earnings Call Commentary)(bps)
-70-80-40-50
Consolidated Constant-Currency Net Sales Growth(%)8
3.7%4.7%6.8%9.2%8.6%5.4%2.3%4.9%4.1%5.6%4.4%6.1%
Knees — Worldwide Constant-Currency Growth(%)2
-2.6%0.1%1.8%6.9%5.3%1.8%1.9%5.6%5.5%5.5%4.3%5.6%
Knees — United States Constant-Currency Growth(%)
-2.0%1.4%2.2%6.0%3.5%1.7%0.2%3.9%2.9%0.8%2.2%5.4%
Knees — International Constant-Currency Growth(%)
-3.4%-1.5%1.3%8.2%7.8%1.8%4.2%8.0%9.2%11.5%7.3%5.8%
Hips — Worldwide Constant-Currency Growth(%)2
7.0%5.1%3.2%4.9%3.8%4.0%2.4%4.0%3.7%2.8%1.5%3.6%
Hips — United States Constant-Currency Growth(%)
5.8%5.9%5.0%7.9%4.0%5.2%3.7%3.2%4.9%1.8%1.0%4.0%
Hips — International Constant-Currency Growth(%)
8.2%4.2%1.0%1.6%3.6%2.7%1.0%4.8%2.4%3.7%2.0%3.2%
S.E.T. (Sports Medicine, Extremities, Trauma, CMFT) — Constant-Currency Growth(%)
7.1%6.2%17.4%18.7%18.2%16.0%4.9%8.4%7.3%7.3%5.3%6.4%
Technology & Data, Bone Cement and Surgical — Constant-Currency Growth(%)1
13.0%21.5%11.7%6.6%11.3%-2.2%-3.5%-4.3%
Other Category — Constant-Currency Growth (Legacy through FY2024Q3)(%)
-9.5%11.3%12.2%15.9%
United States — Constant-Currency Net Sales Growth(%)
3.6%5.6%8.6%11.1%10.6%6.1%1.3%4.7%2.0%3.5%3.7%4.4%
International — Constant-Currency Net Sales Growth(%)
3.9%3.5%4.2%6.6%5.9%4.6%3.7%5.2%7.1%8.5%5.4%8.7%
Organic Constant-Currency Net Sales Growth (Ex-Paragon 28, Legacy through FY2026Q2)(%)3
4.0%2.9%5.4%5.0%2.8%
Foreign Currency Exchange Rate Impact on Net Sales(%)5
-0.6%0.1%2.5%1.7%1.1%1.6%-1.2%-0.6%-0.1%-1.7%-1.2%0.2%
International — Foreign Exchange Impact(%)
-1.5%0.2%6.1%4.0%2.6%3.5%-3.0%-1.5%-0.2%-4.1%-2.9%0.4%
Knees — Foreign Exchange Impact(%)
-0.5%0.3%2.7%1.7%1.0%1.3%-1.3%-0.5%-1.6%-0.9%0.3%
Hips — Foreign Exchange Impact(%)
-1.0%-0.1%2.5%1.9%1.3%1.8%-1.5%-1.0%-0.2%-2.4%-1.8%-0.3%
S.E.T. — Foreign Exchange Impact(%)
-0.3%0.2%2.1%1.4%1.0%1.3%-1.0%-0.4%-1.2%-0.9%0.5%
Technology & Data, Bone Cement and Surgical — Foreign Exchange Impact(%)
-1.1%-0.4%2.9%2.1%1.2%2.0%-1.2%-0.6%
Deployed Surgical Instruments Fleet — Gross Carrying Value($M)6
4,1334,0293,9653,9053,8943,8343,6653,5903,7483,6663,8153,749
Buildings, Machinery & Manufacturing Equipment — Gross($M)
2,4872,4502,4292,4202,4212,4112,3032,2732,3082,2642,2542,246
Capitalized Computer Software — Gross($M)
632620631624612606578575578560555552
Construction in Progress($M)
328298258286273272259234242236206201
Land($M)
22.522.522.522.522.522.618.618.51918.818.818.9
Total Property, Plant & Equipment (Including Instruments) — Gross($M)
7,6027,4197,3057,2577,2227,1466,8236,6906,8966,7456,8496,766
Accumulated Depreciation (Instruments & Other PP&E)($M)
5,2925,1825,0935,0505,0284,9704,7594,6414,7894,6424,7584,706
Surgical Instrument Capital Additions($M)2
11285.477.274.38680.559.751.941.265.28279
Other Property, Plant & Equipment Capital Additions($M)
75.854.236.374.855.15044.651.544.552.755.162.9
Additions to Other Intangible Assets($M)
2562.2391010302.4033.422.35443.35
Share Repurchases — Common Shares Purchased2
821,1282,917,8312,617,1592,711,2422,160,308554,8745,468,000888,000722,7543,770,867
Average Price Paid per Repurchased Share($)
95.5484.6095.5292.21106105109107122116
Remaining Share Repurchase Authorization($M)
9251,0031,2507701,0201,2501,3081,90567.8156
United States Net Sales($M)3
1,2061,2401,2091,3131,1641,1741,1141,1811,0521,1061,0991,128
Knees — United States Net Sales($M)
431455469520440449459490425441458472
Hips — United States Net Sales($M)
280289278293265273264272255259255263
United States — Reported Net Sales Growth(%)2
3.6%5.6%8.6%11.1%10.6%6.1%1.3%4.7%2.0%3.5%3.7%4.4%
Knees — United States Reported Growth(%)
-2.0%1.4%2.2%6.0%3.5%1.7%0.2%3.9%2.9%0.8%2.2%5.4%
Hips — United States Reported Growth(%)
5.8%5.9%5.0%7.9%4.0%5.2%3.7%3.2%4.9%1.8%1.0%4.0%
International Net Sales($M)3
857937877931837904796842772836790812
Knees — International Net Sales($M)
336374359391352377334349320360330327
Hips — International Net Sales($M)
256274247262242264232248227248236242
International — Reported Net Sales Growth(%)2
2.4%3.7%10.3%10.6%8.5%8.1%0.7%3.7%6.9%4.4%2.5%9.1%
Knees — International Reported Growth(%)
-4.5%-0.9%7.6%12.1%10.2%4.8%1.2%6.8%9.1%7.8%5.0%6.7%
Hips — International Reported Growth(%)
6.2%4.0%6.5%5.6%6.4%6.5%-2.0%2.8%1.9%-1.0%-1.7%2.5%
Americas — Operating Profit Margin (Q1 2026 CODM Recast Basis)(%)5
37.9%40.2%40.0%41.2%41.6%42.1%
Americas — Operating Profit Margin (As-Originally-Reported MD&A Basis)(%)
37.9%40.2%40.0%51.6%51.2%51.8%53.3%53.9%
Americas — Segment Cost of Products Sold($M)
296309298278284293268263235249237
Americas — Segment Research & Development Expense($M)
75.971.171.9-21573.773.671.10.900.800.601.20
Americas — Segment Selling, General & Administrative Expense($M)
447433426230388385360314295313309
Americas — Segment Depreciation & Amortization($M)
46.545.144.927.74645.840.738.538.337.136.5
EMEA — Operating Profit Margin (Q1 2026 CODM Recast Basis)(%)5
29.7%31.6%31.1%28.9%33.6%34.1%
EMEA — Operating Profit Margin (As-Originally-Reported MD&A Basis)(%)
29.7%31.6%31.1%29.2%33.9%33.5%32.3%34.4%
EMEA — Segment Cost of Products Sold($M)
163183186196157167166151133151155
EMEA — Segment Research & Development Expense($M)
1.901.901.704.901.801.702.102.602.4022
EMEA — Segment Selling, General & Administrative Expense($M)
130143150147132136123120118128133
EMEA — Segment Depreciation & Amortization($M)
17.116.816.518.516.415.915.615.916.316.916.8
Asia Pacific — Operating Profit Margin (Q1 2026 CODM Recast Basis)(%)5
36.3%30.7%34.2%34.5%36.2%34.1%
Asia Pacific — Operating Profit Margin (As-Originally-Reported MD&A Basis)(%)
36.3%30.7%34.2%35.2%36.6%34.1%39.2%36.2%
Asia Pacific — Segment Cost of Products Sold($M)
1161248812211511883.31039899.775.1
Asia Pacific — Segment Research & Development Expense($M)
2.703.903.3043.303.503.303.303.403.303.30
Asia Pacific — Segment Selling, General & Administrative Expense($M)
88.9107889094.390.785.184.587.285.185.2
Asia Pacific — Segment Depreciation & Amortization($M)
16.315.715.315.815.21515.215.61515.115.4
Total Inventories (Footnote Disaggregation)($M)3
2,3672,2702,2472,2862,4842,4542,2442,2352,3692,3702,3882,385
Finished Goods Inventory($M)
1,9001,8081,7791,8322,0111,9681,7571,7721,8721,8551,8471,831
Work in Process Inventory($M)
180176182181198208215175189216227247
Raw Materials Inventory($M)
288287286273275278272289308299315308
Product Liability & Litigation Reserve($M)4
139138133136147157135156155208227244
Quality & Litigation-Related Charges($M)
17.817.8512.33.105.302.1022.23.803.40117.8
Restructuring & Cost Transformation Charges($M)
14.429.86.3010621.417.53620.932.241.512461.3
2025 Restructuring Program Accrued Liability($M)
35.849.568.899.616.911.413.1
Acquisition, Integration, Licensing & Other Charges($M)
19.618.115.621.9-34.478.910.613.74.405.200.405.30
Free Cash Flow (Non-GAAP)($M)1
37230824636827824827940331025290.9447
Net Debt (Non-GAAP)($M)
7,1047,0697,0476,9276,8207,0165,7925,6795,8825,4155,4035,352
Adjusted Gross Margin (Non-GAAP)(%)3
71.7%71.1%73.0%72.4%72.6%72.3%71.5%71.3%71.0%71.6%72.9%72.5%
GAAP Gross Margin (Earnings Release Reconciliation)(%)
63.1%63.3%64.6%56.8%63.2%63.8%63.3%63.2%62.4%64.1%65.4%64.8%
Adjusted Gross Profit (Non-GAAP)($M)
1,4801,5481,5241,6241,4531,5021,3661,4431,2951,3911,3781,406
Cost of Products Sold (% of Net Sales — MD&A)(%)
28.8%29.2%27.6%27.9%28.5%28.8%29.5%28.5%27.1%
Adjusted Operating Profit Margin (Non-GAAP)(%)5
25.1%25.7%27.3%29.1%26.5%27.8%26.2%30.8%26.3%28.5%28.6%30.3%
GAAP Operating Profit Margin(%)
14.9%15.0%17.9%6.9%17.6%14.4%15.3%19.2%15.3%18.1%14.1%18.3%
Adjusted Operating Profit (Non-GAAP)($M)
519560571653531579501623480553539589
Research & Development (% of Net Sales — MD&A)(%)
5.1%4.8%5.0%5.8%5.5%5.8%6.1%5.6%5.7%
Selling, General & Administrative (% of Net Sales — MD&A)(%)
41.4%41.3%40.7%40.5%39.2%39.7%38.9%38.0%39.0%
Intangible Assets Amortization (% of Net Sales — MD&A)(%)
8.0%7.5%7.8%8.8%7.7%7.9%8.1%7.4%7.5%
Adjusted Diluted Earnings per Share (Non-GAAP)($)3
1.902.072.092.421.902.071.812.311.742.011.942.20
Adjusted Net Earnings (Non-GAAP)($M)
363400409480377411361462353415400458
Adjusted Effective Tax Rate (Non-GAAP)(%)
17.6%18.0%18.0%17.9%17.8%18.2%18.2%17.5%17.7%18.2%18.5%15.8%
GAAP Effective Tax Rate(%)
16.2%21.8%20.9%-40.7%17.2%31.7%20.3%16.9%-8.2%19.6%19.7%-47.6%
CEO to Median Employee Pay Ratio (DEF 14A)1
Pre-Tax Share-Based Compensation Expense($M)
24.224.624.224.125.321.219.621.124.526.42925.3
Paragon 28 — Worldwide Foot & Ankle Net Revenue (Pre-Acquisition through FY2024Q4)($M)
71.862.361.061.160.6
Paragon 28 — Deployed Surgical Instruments, Gross (Pre-Acquisition through FY2024)2
Paragon 28 — Property & Equipment, Net (Pre-Acquisition through FY2024Q4)($M)
71.474.074.975.774.1
Paragon 28 — Inventories, Net (Pre-Acquisition through FY2024Q4)($M)
90.096.596.494.690.1
Paragon 28 — Gross Profit (Pre-Acquisition through FY2024Q4)($M)4
52.346.245.847.242.4
Paragon 28 — Research & Development Expense (Pre-Acquisition through FY2024Q4)($M)
6.745.667.087.588.10
Paragon 28 — Selling, General & Administrative Expense (Pre-Acquisition through FY2024Q4)($M)
52.049.049.454.848.3
Paragon 28 — Operating Loss (Pre-Acquisition through FY2024Q4)($M)
-6.44-8.45-10.8-15.1-14.0
Paragon 28 — Operating Cash Flow (Pre-Acquisition through FY2024Q4)($M)
-3.28-2.67-10.2-11.0-16.4
Monogram Technologies — Robotics R&D Expense (Pre-Acquisition through FY2025Q2)($M)5
2.262.261.742.212.432.413.01
Monogram Technologies — General & Administrative Expense (Pre-Acquisition through FY2025Q2)($M)
0.771.031.121.091.121.081.08
Monogram Technologies — Operating Loss (Pre-Acquisition through FY2025Q2)($M)
-3.07-3.33-2.92-5.15-3.63-3.61-3.88
Monogram Technologies — Operating Cash Outflow (Pre-Acquisition through FY2025Q2)($M)
-2.30-2.31-3-4.49-2.83-3.65-3.11
Monogram Technologies — Cash & Cash Equivalents (Pre-Acquisition through FY2025Q2)($M)
12.813.315.716.67.3110.113.6
Monogram Technologies — Total Assets (Pre-Acquisition through FY2025Q2)($M)
1515.417.820.29.8212.516.6
FDA 510(k) Premarket Clearances — Zimmer Biomet1
4115272366525
U.S. Orthopedic Industry Total — FDA 510(k) Clearances
856923756806797886736856767793713877
FDA PMA Premarket Approvals & Supplements — Zimmer Biomet1
634033042222
U.S. Orthopedic Industry Total — FDA PMA Approvals & Supplements
565608567525585588524683538550459656
FDA Device Recall Events (openFDA Database) — Zimmer Biomet1
772221552324222
FDA Recall Enforcement Reports — Zimmer Biomet
1312230642423222
FDA MAUDE Adverse Event Reports — Zimmer Biomet4
2,9493,5452,9754,2245,7285,4944,6955,0664,5315,1374,6244,781
FDA MAUDE — Device Malfunction Reports
1,4101,3411,3551,5351,7001,6221,5701,7351,3391,5051,5501,730
FDA MAUDE — Patient Injury Reports
1,5172,1931,5862,6854,0053,8633,1253,3293,1863,6323,0733,049
FDA MAUDE — Patient Death Reports
1311334239006012
U.S. Orthopedic Panel — Total Industry MAUDE Reports
1,189,695923,529811,618751,012819,444632,296685,251709,498699,798631,546586,309573,619
U.S. Federal Orthopedic Prime Contract Obligations — Zimmer Biomet (USAspending.gov)($M)
0.860.285.115.076.586.635.465.615.805.836.625.57
U.S. Producer Price Index — Surgical Appliance & Supplies Mfg / Orthopedics (NAICS 339113)1
U.S. General Medical & Surgical Hospitals Revenue (Census QSS)($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
Consolidated Net Sales (GAAP)($M)5
2,0632,1772,0872,2442,0012,0771,9092,0231,8241,9421,8891,940
Cost of Products Sold, Excluding Intangible Amortization (GAAP)($M)
595636576792559592550587539554512539
Research & Development Expense (GAAP)($M)
106105103119116113111109112109108113
Selling, General & Administrative Expense (GAAP)($M)
855899850872811815759747710737736722
Operating Profit (GAAP)($M)
308326373155351300292389280351266354
Net Earnings Attributable to Zimmer Biomet (GAAP)($M)
192198238139231153182240249243172419
Net Cash Provided by Operating Activities (GAAP)($M)1
560448359517419378383506396369228588
Additions to Other Property, Plant & Equipment (GAAP Cash Flow Statement)($M)
75.854.236.374.85550.144.651.544.552.755.162.8
Total Assets (GAAP)($M)7
23,53922,79822,72223,09223,48822,86522,18421,36521,72021,52021,45221,497
Cash & Cash Equivalents($M)
4004104245921,2935571,385526569420393416
Inventories (GAAP Balance Sheet)($M)
2,3672,2702,2472,2862,4842,4542,2442,2352,3692,3702,3882,385
Property, Plant & Equipment, Net (Includes Net Instruments)($M)
2,3102,2372,2122,2072,1942,1762,0652,0492,1072,1032,0912,060
Goodwill($M)
10,3369,9209,9329,9479,7029,7108,9898,9518,9128,8258,7928,819
Intangible Assets, Net($M)
4,6354,4624,5484,7174,7404,8914,4684,5984,6654,7074,7344,856
Long-Term Debt($M)
6,2176,2786,2956,9327,5136,7536,5765,3424,7383,9574,8264,868
Total Stockholders' Equity($M)
12,71612,62412,67312,69812,75712,52512,39512,46812,37512,74112,59812,481

52 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Core Orthopedic Operational Drivers: Procedure volume and product mix growth effect, global selling price realization (both 10-Q/10-K MD&A % and quarterly earnings call basis points including Q4), management's guided constant-currency net sales growth across Knees, Hips, S.E.T., and Technology & Data, and the $4.13B gross deployed surgical instrument fleet consigned across hospitals and ambulatory surgery centers (ASCs).
  • Surgical Instrument Capital Expenditure Distinction: In orthopedic reconstruction, Zimmer Biomet consigns reusable surgical instrument trays to hospitals and ASCs and reports 'Additions to instruments' ($300.5M in FY2025; $111.8M in Q3 2026) on a separate cash flow line from 'Additions to other property, plant and equipment' ($224.5M in FY2025; $75.8M in Q3 2026). Both capital outflows are deducted in Free Cash Flow.
  • Q1 2026 Regional Segment Cost-Allocation Recast & Paragon 28 Anniversary: In Q1 2026, Zimmer Biomet moved EMEA/APAC Foot & Ankle results and centralized R&D and global marketing expenses into Americas operating profit, recasting FY2025 quarterly comparatives. Paragon 28 (acquired April 21, 2025) was tracked separately in Organic Constant-Currency Growth through Q2 2026 and became fully organic in Q3 2026.
  • Subsidiary & Statutory Filings: Zimmer Biomet files consolidated U.S. GAAP financial statements without standalone parent-company schedules. Pre-acquisition SEC filings of acquired subsidiaries Paragon 28, Inc. (through FY2024Q4) and Monogram Technologies Inc. (through FY2025Q2), along with annual UK statutory Gender Pay Gap filings for Zimmer Biomet's UK operating subsidiaries through FY2025, are presented in dedicated subsidiary groups.
  • Derived Period Splits: Only cumulative year-to-date cash flow and XBRL subtractions (YTD − prior YTD for Q2/Q3 and FY − 9M / Q4 = full year − nine months for Q4) are used where quarterly filings report cumulative figures.

Không hiện vì thiếu các kỳ gần đây (14)

  • ROSA Surgical Robotics Global Installed Base ('more than 2,000 units') — Disclosed only with lower-bound qualifiers in earnings calls and presentations without exact quarterly installed unit tables.
  • Z1 Triple-Taper Hip Stem Share of U.S. Hip Stems ('over 35%' in Q4 2025, 'about 40%' in Q2 2026, 'over 50%' in Q3 2026) — Qualified as bounds in Q4 2025 and Q3 2026.
  • Persona OsseoTi Cementless Knee Penetration in the U.S. (~35% in Q4 2025, >50% long-term target) — Point penetration disclosed in only a single recent period.
  • Oxford Cementless Partial Knee Market Share ('over 20%') & HAMMR Automated Hip Impactor Share ('nearly 30%') — Disclosed only as bound estimates on earnings calls.
  • Active Global Patents & Patent Applications ('over 6,000' / 'more than 6,500') and Countries Served ('more than 25' direct / 'more than 100' distribution) — Disclosed only as lower bounds in Form 10-K.
  • Global Employee Headcount in Form 10-K ('approximately 17,000' in FY2025, 'approximately 18,000' in FY2024) — Rounded to nearest thousand in Form 10-K; exact DEF 14A pay-ratio employee counts (17,149 in FY2025, 18,042 in FY2022, 20,122 in FY2020) are determined once every 3 years and therefore non-consecutive.
  • Global Female Workforce Share & Director+ Share (Sustainability Reports) — Reported for FY2020–FY2023 (37%–39% workforce) but discontinued in the 2024 and 2025 Sustainability Reports.
  • Dental & Spine / ZimVie Pre-Spin-Off Product Categories (FY2016–FY2021) — Discontinued following the March 1, 2022 spin-off of ZimVie Inc.
  • Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) › Biomet 3i UK Limited — Mean Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.
  • Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) › Biomet 3i UK Limited — Median Bonus Gender Gap (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.
  • Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) › Biomet 3i UK Limited — Female Share in Top Pay Quartile (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.
  • Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) › Biomet 3i UK Limited — Female Employees Receiving Bonus (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.
  • Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) › Biomet 3i UK Limited — Male Employees Receiving Bonus (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.
  • Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.

Dữ liệu cập nhật 2026-11-14.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Monogram Technologies Inc. — Acquired Surgical Robotics Subsidiary (Pre-Acquisition through FY2025Q2)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Zimmer Biomet

See a number that looks wrong?